Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial.
St. John 's Wort ( Hypericum perforatum L. ) is a useful medication in the treatment of mild to moderate depression . By re analysis of the data obtained from a total of 154 patients , who responded in a r and omised , multicentric , double-blind , placebo-controlled study , to 6 weeks of treatment for an episode of moderate depression with either 20 mg citalopram or 900 mg Hypericum extract STW 3-VI , the duration of response and occurrence of relapse/recurrence were evaluated . Duration of response and occurrence of relapse/recurrence was measured by re-evaluating the responders in a controlled- clinical trial ( final score of ≤10 according to HAMD at the end of the clinical trial ) according to the Hamilton Rating Scale for Depression ( HAMD ) . In total , 30 ( 19.5 % ) of the 154 responders were diagnosed with a relapse . The numbers of patients with relapses were highest in the citalopram group ( 14 of 54 ) , whereas patients who were treated with Hypericum extract STW 3-VI showed the lowest relapse rate ( 8/54 ) ; patients from the placebo group showed a relapse rate of 8/46 . No difference in the severity of relapse could be observed . The duration of response was longest for the Hypericum group ( 1817 days ) , intermediate for the citalopram group ( 1755 days ) and shortest for the placebo group ( 802 days ) . Hypericum extract STW 3-VI is more efficient in lowering the relapse and recurrence rates of responders , when compared to citalopram and placebo . In addition , duration of response was increased in the group treated with Hypericum extract STW 3-VI
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .